The premier ratings on Bristol-Myers Squibb Co. reflect the company's continuing position as one of the world's largest pharmaceutical firms, its long record of successful drug development, a diverse revenue base, and solid cash flows. New York City-based Bristol-Myers Squibb Co. has announced that it has entered into an agreement with biotech firm, ImClone Systems, to codevelop and copromote ImClone's promising cancer treatment, IMC-C225. Under the agreement, Bristol-Myers will commit upwards of $1 billion in funding, based on certain milestones, for the development of IMC-C225, as well as acquire roughly 20% of ImClone for $1 billion. The deal is the latest in a series of recent strategic moves by Bristol-Myers to increase its focus on its core pharmaceutical business. Earlier
